-
ASCO 2022: Top 10 Most Anticipated Breast Cancer Studies
Time of Update: 2022-08-12
1. Randomized Phase III clinical trial:To evaluate the efficacy of sacituzumab govitecan versus physician's choice of treatment in patients with HR+/HER2- advanced breast cancerSpeaker: Hope RugoAbstract ID: LBA1001Why it's on the list: Could registry data in HR-positive breast cancer add to another indication for goxatuzumab in addition to triple-negative breast cancer?
-
Biositu/Uho Pharma will present the latest clinical study data of its CD40 mAb and CTLA-4 mAb at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Time of Update: 2022-08-12
Corresponding author: Dr. Jermaine Coward clinical trial number : NCT04481009 Abstract ID: 2603 Session: Poster Session 3: Developmental Therapeutics—ImmunotherapyTitle: A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb), in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.
-
5.29 "World Gut Health Day": Yakult calls on you to "benefit", balance "intestine" and enjoy health
Time of Update: 2022-08-11
There are "benefits" and "benefits" pay attention to the new "intestinal" state of healthIn order to cooperate with this year's "World Intestinal Health Day" theme event, Yakult is more than "Beneficial Says Yi" official popular science WeChat public account to launch original popular science videos "Food's Digestive Tract Adventures" and interactive H5 "My Bacteria Balance Intestine Enjoy Health" Action" .
-
China Fund News: Mindray Medical's two-wheel drive at home and abroad grasps the dividends of industry development
Time of Update: 2022-08-11
62em; font-family:"Arial"; color:black; margin:0in; } >Medical market demand grows steadilyShenzhen , May 27, 2022 /PRNewswire/ -- Recently, Mindray Medical stated in Interactive Yi that the medical device industry is not optional consumption, no matter in any period and in any environment, the demand for medical care is growing steadily, so , the procurement of medical devices will continue, but the needs of procurement will change with the changing environment .
-
The first exhibition of Hangzhou Bo's resumption of work in July is ready to go: 200+ heavyweight speakers, more than 5,000 people in the biopharmaceutical circle have pre-registered!
Time of Update: 2022-08-11
The 9th International Biopharmaceutical Conference and Exhibition of BioCon Expo will start from July 20-22 at Hangzhou International Expo Center . "BioCon Awards", as a new authoritative biomedical a
-
Burning Rock Medicine: Is your gut "it" good when you're at home?
Time of Update: 2022-08-11
The days of a single diet, high emotional stress, and greatly reduced physical activity have turned home office into a "Petri dish" for bad living habits, which virtually increases the risk of disease, especially the risk of colorectal cancer .
-
Yunnan will still develop vaccine-focused biotech drugs in the next five years
Time of Update: 2022-05-26
(Finish) In recent years, the biotechnology drug industry focusing on vaccines has become the fastest growing field in the biopharmaceutical industry in Yunnan Province .
(Finish) In recent years, the biotechnology drug industry focusing on vaccines has become the fastest growing field in the biopharmaceutical industry in Yunnan Province .
-
WuXi AppTec was named "2022 ESG Industry's Highest Rated Company" by Sustainalytics
Time of Update: 2022-05-25
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
62em; font-family:"Arial"; color:black; margin:0in; } </>SHANGHAI, April 8, 2022 /PRNewswire/ -- Recently, WuXi AppTec was awarded the "2022 ESG (Environmental, Social and Governance) Industry's Highest Rating Enterprise" by Sustainalytics, a well-known international rating agency .
-
[First Release] The 9th BioCon Expo top-level luxury lineup of biological drugs is ready to go, unlock the mysterious surprise of pre-registration
Time of Update: 2022-05-25
From May 31st to June 2nd, the 9th International Biopharmaceutical Conference and Exhibition of BioCon Expo will be registered in Hangzhou International Expo Center . In the exhibition area expected
-
Tianyan Pharmaceuticals Announces Data on Multiple Highly Differentiated, First-in-Class or Best Potential Preclinical Antibody Candidates at the 2022 American Cancer Society Annual Meeting
Time of Update: 2022-05-25
62em; font-family:"Arial"; color:black; margin:0in; } </>-Four posters show the application of safe antibody SAFEbody™ precision masking technology in multiple targets and different therapies -Plan to submit IND or similar clinical applications for new product candidates in 2022 , including Fc -optimized anti- CD137 and anti- CD47 safety Antibodies designed to improve both safety and efficacySuzhou, China and San Diego , U.
-
BeiGene to Present Clinical Results and Biomarker Data of Tislelizumab in Solid Tumors Program at American Association for Cancer Research (AACR) 2022 Annual Meeting
Time of Update: 2022-05-25
50em } RATIONALE303 and RATIONALE304 sub-analysis data further support the potential of tislelizumab in the treatment of non-small cell lung cancerBiomarker study reveals patient characteristics that predict better response to PD-(L)1 inhibitor therapyBEIJING, China, CAMBRIDGE, MA, USA and BASEL, Switzerland, April 8, 2022 /PRNewswire/ -- BeiGene (NASDAQ: BGNE; HK: 06160; S: 688235) is A global, science-based biotechnology company focused on developing innovative, affordable medicines that improve outcomes and access to medicines for patients around the world .
-
Ganlai Announces First Patient Dosing in Phase II Clinical Trial of FXR Agonist ASC42 in Primary Biliary Cholangitis
Time of Update: 2022-05-24
(SEHK: 1672), today announced that ASC42 has been used in the treatment of primary The first patient has been dosed in a Phase II clinical trial of biliary cholangitis (PBC) .
New drugs targeting FXR are also being developed for the treatment of primary biliary cholangitis .
-
The annual sales volume of Yuyue oxygen concentrator is the first in the world to exceed 1 million units
Time of Update: 2022-05-24
62em; font-family:"Arial"; color:black; margin:0in; } </>Nanjing, April 11, 2022 /PRNewswire/ -- Recently, Yuyue Medical officially announced that the global annual sales volume of oxygen concentrators exceeded 1 million units, taking the lead in breaking the million mark in the industry .
-
Hainan Bite Voriconazole for Injection is approved for production and deemed to have been reviewed
Time of Update: 2022-05-24
In recent years, among the terminal systemic antifungal chemical products in China's public medical institutions, voriconazole for injection has ranked first.
In recent years, among the terminal systemic antifungal chemical products in China's public medical institutions, voriconazole for injection has ranked first.
-
"Dragon Spaceship" carried ACC amorphous calcium and many black technology experimental missions into space
Time of Update: 2022-05-24
During these eight days, the four astronauts will join other astronauts in the space station on 35 new scientific experimental missions approved by NASA's "Rakia" project .
-
New Zealand's pioneering cell health brand MitoQ innovates scientific videos to unlock new health
Time of Update: 2022-05-24
Professor Mike Murphy, co-founder scientist of the MitoQ®️ moleculeTo solve this problem, MitoQ's exclusive patented antioxidant technology MitoQ®️ molecule was born, which breaks the conventional antioxidant form and is a smaller, positively charged antioxidant that can penetrate the negative charge of mitochondria The double-walled membrane greatly increases the absorption efficiency, can effectively control the balance of free radicals, effectively fight against cellular stress, and improve overall health .
-
Innovent Announces Preliminary Results of a Phase I Clinical Study of IBI322 (PD-L1/CD47 Bispecific Antibody) at the 2022 AACR Annual Meeting in Subjects with Advanced Malignancies who Failed Standard Therapy
Time of Update: 2022-05-24
<> /* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prne
-
[Friends Round Table Party] Yu Guoliang, Yang Qing, Wang Jian, and Shi Chenyang, friends of more than 20 years, talk about "entrepreneurship" together!
Time of Update: 2022-05-24
After more than 20 years of friendship, we jointly launched the "Friends Round Table Party" with Yimao Medical to talk about "entrepreneurship"!April 13th, 20:00 —— The online live broadcast of Yimao Medical is not to be missed!
-
Entrusted by the New Frontier Group of the Hong Kong SAR Government to join hands with Hong Kong to fight the epidemic
Time of Update: 2022-05-24
Through its subsidiary Toby in Hong Kong, New Frontier Tianyu has coordinated a number of experienced nursing staff; New Frontier Tianyu's institutions such as United Family Healthcare, Gulian Medical, and Yi Dekang Medical have also relied on their rich experience in anti-epidemic and elderly care.
-
Empowering the construction of specialists to create a healthy China "Breast Cancer Scientific Management Promotion Project" launched
Time of Update: 2022-05-24
<> /* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prne
